Оценка клинико-функционального состояния и качества жизни больных хронической обструктивной болезнью легких до и после комплексной медикаментозной терапии в амбулаторных условиях

A comparative randomised trial of fenspirid (Erespal) had been administered for 3 months together with bronchodilating and mycolytic drugs involved 45 patients with chronic obstructive pulmonary disease (COPD). Clinical status, forced expiratory values and quality of life (QoL) were studied using World Organization of Health questionnaire (W H O Q O L -100). Thirty four patients completed the examination (24 males and 10 females, the average age was 52.7±1.9 yrs). The comparative group included 25 healthy non-smokers. The trial demonstrated that the therapy resulted in improvement of QoL in physical and psychical health scales. The patients becam e more active, their sleep becam e better. Their attention was transferred from their physical status to the surroundings. The application of fenspirid (Erespal) facilitated the improvement in the forced expiratory values and ESR. The drug was well tolerated and caused only mild adverse effects which rates were equal to those in patients not received fenspirid. The results permit fenspirid to be included to modern treatment protocols for patients with mild to moderate COPD when combined with bronchodilators.